Electronic drug delivery systems market seen reaching $19.44 billion by 2030

The global electronic drug delivery systems market is projected to grow from $11.93 billion in 2025 to $13.11 billion in 2026, then climb to $19.44 billion by 2030, according to The Business Research Company. Growth is being driven by chronic disease prevalence, personalized medicine, and wider adoption of connected, monitored treatment tools.

Why it matters: - Electronic drug delivery systems are becoming more important as chronic diseases rise and treatment moves toward personalized, monitored care. - The market is expanding because patients and providers want more controlled dosing, better adherence, and easier management of long-term therapies. - The shift matters for home healthcare, remote monitoring, and digital health programs that rely on connected treatment tools.

What happened: - The Business Research Company released its Electronic Drug Delivery Systems Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Aug. 6, 2026. - The report says the market will grow from $11.93 billion in 2025 to $13.11 billion in 2026. - The report projects the market will reach $19.44 billion by 2030. - The report places North America as the largest market in 2025. - The report identifies Asia-Pacific as the fastest-growing region during the forecast period. - A free sample of the report is available here. - The full report is available here.

The details: - The market’s 2025-to-2026 growth rate is projected at 9.9%. - The report forecasts a 10.4% compound annual growth rate through 2030. - The historical growth drivers include rising chronic disease rates, broader availability of injectable and inhalable therapies, more infusion treatment use, growing home healthcare adoption, and wider access to electronic delivery platforms. - Future growth is expected to come from demand for personalized drug delivery, adoption of digital health ecosystems, expansion of remote patient monitoring, and a greater focus on adherence-driven outcomes. - Expected product trends include smart drug delivery devices, connected and wearable systems, precise dose-control technologies, patient self-administration tools, and better monitoring of therapy adherence. - Electronic drug delivery systems are devices or formulations designed to deliver medication directly to targeted areas of the body while avoiding non-target tissues. - These systems support controlled and consistent dosing, easier dose monitoring, and better treatment management. - Chronic diseases, which last longer than a year and require ongoing care, are a major driver for these systems. - The National Library of Medicine in January 2023 projected that the U.S. population age 50 and older with at least one chronic condition will reach 142.66 million by 2050. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The forecast points to a market that is moving beyond basic drug delivery and toward digitally connected treatment management. - The combination of chronic disease growth and adherence pressure suggests demand will favor systems that can track use, support self-administration, and integrate with wider care platforms. - Regional leadership in North America and faster growth in Asia-Pacific suggests mature markets may drive scale while emerging markets add momentum.

What's next: - The report expects smart, connected, and wearable delivery tools to shape the market through 2030. - Remote patient monitoring and digital health integration are likely to remain central to product development and market expansion. - Wider chronic disease incidence should continue to support demand for regulated, long-term drug delivery systems.

The bottom line: - Electronic drug delivery systems are moving from niche tools to a fast-growing part of chronic care, with the market projected to approach $19.44 billion by 2030.